Schonfeld Strategic Advisors LLC Invests $2.68 Million in Twist Bioscience Co. (NASDAQ:TWST)

Schonfeld Strategic Advisors LLC bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 57,598 shares of the company's stock, valued at approximately $2,677,000. Schonfeld Strategic Advisors LLC owned approximately 0.10% of Twist Bioscience as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of TWST. Van ECK Associates Corp grew its stake in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Twist Bioscience in the third quarter valued at approximately $34,000. US Bancorp DE raised its stake in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the period. KBC Group NV lifted its position in shares of Twist Bioscience by 71.4% during the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after purchasing an additional 1,226 shares in the last quarter. Finally, Wealthfront Advisers LLC purchased a new position in shares of Twist Bioscience in the fourth quarter valued at $209,000.

Wall Street Analyst Weigh In

TWST has been the topic of a number of recent analyst reports. Barclays cut their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. JPMorgan Chase & Co. raised their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Robert W. Baird upped their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research report on Tuesday, February 4th. Finally, Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research report on Friday, March 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $52.80.

Twist Bioscience Stock Up 4.1 %

TWST stock opened at $39.24 on Monday. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -11.61 and a beta of 2.54. Twist Bioscience Co. has a 1-year low of $33.16 and a 1-year high of $60.90. The firm has a fifty day moving average price of $39.24 and a two-hundred day moving average price of $44.06. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. During the same quarter last year, the company posted ($0.75) earnings per share. Twist Bioscience's revenue was up 24.1% on a year-over-year basis. Research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Buying and Selling

In related news, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $98,265.82. Following the sale, the chief executive officer now owns 662,692 shares of the company's stock, valued at $27,110,729.72. This trade represents a 0.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert Chess sold 2,940 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the transaction, the director now directly owns 18,173 shares of the company's stock, valued at $965,531.49. The trade was a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,137 shares of company stock worth $530,112 in the last three months. 3.01% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.